Latest Posts

Drs. Mackman and Hisada published an invited review article entitled “Mechanisms of cancer-associated thrombosis” in Research and Practice in Thrombosis and Haemostasis. In the review, they described 4 pathways of cancer-associated thrombosis including tissue factor-positive extracellular vesicles, podoplanin, neutrophil extracellular traps and plasminogen activator inhibitor-1. This review article is based...

Erica Sparkenbaugh, PhD was awarded a one-year Stage 1 SBIR grant from NHLBI (HL169107-01) titled Allosteric Modulation of PAR1 for the Treatment of Sickle Cell Disease.  She is a subcontract on the grant with Chris Dockendorff at Function Therapeutics as PI.

Yasmina Abajas’, MD paper ‘Current practices in pediatric hospital-acquired thromboembolism: Survey of the Children’s Hospital Acquired Thrombosis (CHAT) Consortium’ was published in the Research and Practice in Thrombosis and Haemostasis journal.   Click here to read the paper.

The results of 2 phase 3 trials of AAV-mediated gene therapy for hemophilia A and hemophilia B were published back-to-back in the New England Journal of Medicine on February 23, 2023.  Dr. Nigel Key was a collaborator and co-author on both studies, each of which included patients from UNC. The...

Sickle cell disease carries a significant risk of venous thrombosis, yet evidence suggests that anti-coagulant therapy increases the risk of bleeding in individuals with SCD. Coagulation FXII, which contributes to thrombosis but not hemostasis, is an appealing target for treating thrombosis without carrying a bleeding risk. Work led by Erica...

Dr. Callie Berkowitz, a second year hematology fellow, has been selected for the Promoting XXcellence in Women’s Health: Optimal Management of Women and Girls with Bleeding Disorders special research award from the Foundation for Women and Girls with Blood Disorders. Her project will explore hemostatic outcomes and patients needs in...

Click here to read the February 2023 Newsletter

Antoniak Lab published a study investigating the role of thrombin-PAR1 signaling in chemotherapy induced heart failure. UNC Blood Research Center researchers Drs Grover, Bharathi, Mackman and Antoniak in collaboration with Drs. Posma, Griffin and Palumbo published in Blood Advances “Thrombin mediated activation of PAR1 enhances doxorubicin induced cardiac injury in...

The contact pathway of coagulation has been implicated in the pathogenesis of venous thrombosis. Relatively little, however,  is known about the the role of C1 inhibitor, the major negative regulator of this pathway, in venous thrombosis. Work led by Steven Grover and Nigel Mackman revealed that C1 inhibitor deficiency, resulting...

Work led by postdoctoral fellow Jun Wan, PhD under the supervision of Steven Grover, PhD and Nigel Mackman, PhD establishing a novel mouse whole blood thrombin generation assay has been published in the Journal Blood Advances. In this work the authors found that the novel mouse whole blood assay provided...

Congratulations to Research Assistant Professor Steven Grover, PhD who received a 2023 UNC Junior Faculty Development Award to support his work studying “The role of endogenous C1 inhibitor as a negative regulator of coagulation in the general population”. This highly competitive award is supported by the UNC Office of the Provost with...

Rafal Pawlinski, PhD and Jian Liu, PhD were published in the Proceedings of the National Academy of Sciences (PNAS) Journal for their paper, “Using heparan sulfate octadecasaccharide (18-mer) as a multi-target agent to protect against sepsis”. Click here to read the paper.